MITIGARE

Peak

colchicine

NDAORALCAPSULE
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
14

Mechanism of Action

Colchicine's effectiveness as a treatment for gout has been postulated to be due to its ability to block neutrophil-mediated inflammatory responses induced by monosodium urate crystals in synovial fluid. Colchicine disrupts the polymerization of β-tubulin into microtubules, thereby preventing the…

Pharmacologic Class:

Alkaloid

Clinical Trials (5)

NCT06666335Phase 4Not Yet Recruiting

A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF

Started Sep 2025
3 enrolled
Familial Mediterranean Fever (FMF )
NCT06543082Phase 4Recruiting

MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

Started Aug 2024
490 enrolled
Acute Coronary Syndrome
NCT04516941Phase 3Terminated

CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19

Started Jan 2021
60 enrolled
SARS-CoV InfectionCOVID-19
NCT04139655N/AWithdrawn

Colchicine Prevents Myocardial Injury After Non-Cardiac Surgery Pilot Study

Started Sep 2020
0
Myocardial InfarctionMyocardial InjuryMajor Adverse Cardiac Events+1 more
NCT01709981Phase 4Completed

Anti-inflammatory Effects of Colchicine in PCI

Started May 2013
280 enrolled
Coronary Artery Disease

Loss of Exclusivity

LOE Date
Aug 22, 2033
90 months away
Patent Expiry
Aug 22, 2033

Patent Records (5)

Patent #ExpiryTypeUse Code
8927607
Aug 22, 2033
U-1020
9399036
Aug 22, 2033
U-1020
9555029
Aug 22, 2033
U-1020
9675613
Aug 22, 2033
U-1020
9789108
Aug 22, 2033
U-1020